4.10
0.10 (2.50%)
| Previous Close | 4.00 |
| Open | 4.00 |
| Volume | 329,319 |
| Avg. Volume (3M) | 687,676 |
| Market Cap | 230,437,360 |
| Price / Book | 1.22 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2026 |
| Diluted EPS (TTM) | -1.49 |
| Total Debt/Equity (MRQ) | 2.67% |
| Current Ratio (MRQ) | 18.03 |
| Operating Cash Flow (TTM) | -40.14 M |
| Levered Free Cash Flow (TTM) | -26.32 M |
| Return on Assets (TTM) | -27.16% |
| Return on Equity (TTM) | -41.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Protara Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.83 |
|
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.61% |
| % Held by Institutions | 76.24% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |